The firms said that the deal will provide access to Tempus' testing menu for healthcare providers at 800 cancer care locations that use Flatiron's OncoEMR platform.

NEW YORK – Autoimmune testing firm Exagen on Tuesday announced its Q3 revenues declined 7 percent year over year. For the three months ended Sept. 30, the firm posted revenues of $12.5 million, down ...

Last week, readers were most interested in a story about Tempus' expectations for its acquisition of cancer testing firm Ambry.

The certification is for products used in hematology instruments manufactured globally, including instruments from Abbott, Beckman Coulter, and Siemens Healthineers.

The research team looked at cell-free DNA fragmentation profiles across the genome combined with measurements of two key biomarkers to detect ovarian cancer.

The US Food and Drug Administration granted clearances for various tests for infectious diseases, coagulation disorders, and drug susceptibility.

The firm said that demand has increased for its 10-minute sepsis risk test as it can save lives, reduce hospital stays, and reduce healthcare costs.

NEW YORK – Adaptive Biotechnologies on Thursday reported a 22 percent increase in Q3 revenues driven by an increase in minimal residual disease testing.

SensID manufactures reference materials and quality controls for molecular diagnostics with a focus on oncology and precision medicine.

The firm said on Wednesday that it has been hiring key sales and marketing personnel as it prepares to ramp up sales in 2025 of its PreTRM proteomic test.

Last week, readers were most interested in a story about the FDA's clearance of Qiagen's QiaStat-Dx Respiratory Panel Mini syndromic multiplex qPCR test.

The firm's Q3 2024 revenues rose 33 percent year over year as both its genomics and data and services revenues increased in the double-digit percent range.